



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** February 5, 2010

**To:** NCCTG Primary Clinical Research Associates

**From:** Janis Wobschall  
Research Protocol Specialist

**Re:** N027D, A Phase I Study of CCI-779 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

The End of Active Treatment/Cancel Notification Form has been revised as follows:

<b>Form Title</b>	<b>Brief Description of Edit</b>
End of Active Treatment/Cancel Notification Form	Section header "This patient will now go to" <b>Read:</b> <ul style="list-style-type: none"><li>• 9 - Off Study (<i>cancel only</i>)</li></ul> <b>Now reads:</b> <ul style="list-style-type: none"><li>• 9 - Off Study</li></ul>

If you have any questions, please feel free to contact me at 507/284-4852.

JW/dg  
Enclosure